Zhangzhou Pientzehuang Pharmaceutical., Ltd

SHSE:600436 Stock Report

Market Cap: CN¥94.8b

Zhangzhou Pientzehuang Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Zhangzhou Pientzehuang Pharmaceutical has been growing earnings at an average annual rate of 9.3%, while the Pharmaceuticals industry saw earnings growing at 4.7% annually. Revenues have been growing at an average rate of 10.2% per year. Zhangzhou Pientzehuang Pharmaceutical's return on equity is 16%, and it has net margins of 24.7%.

Key information

9.29%

Earnings growth rate

9.28%

EPS growth rate

Pharmaceuticals Industry Growth10.90%
Revenue growth rate10.20%
Return on equity16.03%
Net Margin24.74%
Next Earnings Update30 Apr 2026

Recent past performance updates

Recent updates

There's Reason For Concern Over Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Price

Mar 10
There's Reason For Concern Over Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Price

Revenue & Expenses Breakdown

How Zhangzhou Pientzehuang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:600436 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 259,7802,420852305
30 Jun 2510,5162,698855274
31 Mar 2510,7593,002789252
31 Dec 2410,7882,977861270
30 Sep 2410,9093,0791,095197
30 Jun 2410,6642,9781,142232
31 Mar 2410,6003,0021,166228
31 Dec 2310,0582,7971,162232
30 Sep 239,6782,825857267
30 Jun 239,3172,699779236
31 Mar 238,9752,553797245
31 Dec 228,6942,472808230
30 Sep 228,5262,473878245
30 Jun 228,5952,631941249
31 Mar 228,3682,5561,024256
31 Dec 218,0222,4321,034200
30 Sep 217,5532,354955103
30 Jun 217,1131,9221,061104
31 Mar 216,7981,7691,00189
31 Dec 206,5111,67298498
30 Sep 206,4511,5941,017126
30 Jun 206,0741,493901122
31 Mar 205,9521,438865132
31 Dec 195,7221,374799119
30 Sep 195,5221,332712141
30 Jun 195,2571,272659125
31 Mar 195,0281,221645108
31 Dec 184,7661,143629101
30 Sep 184,5551,05268574
30 Jun 184,36599165998
31 Mar 184,07690764782
31 Dec 173,71480761170
30 Sep 173,42873056441
30 Jun 173,1016645710
31 Mar 172,7006165200
31 Dec 162,3095364890
30 Sep 162,1805754260
30 Jun 162,0325203950
31 Mar 161,9754973630
31 Dec 151,8864673390
30 Sep 151,6985133000
30 Jun 151,5034742800
31 Mar 151,4554402690

Quality Earnings: 600436 has a high level of non-cash earnings.

Growing Profit Margin: 600436's current net profit margins (24.7%) are lower than last year (28.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600436's earnings have grown by 9.3% per year over the past 5 years.

Accelerating Growth: 600436's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600436 had negative earnings growth (-21.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6.5%).

Return on Equity

High ROE: 600436's Return on Equity (16%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/10 08:34
End of Day Share Price 2026/03/10 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhangzhou Pientzehuang Pharmaceutical., Ltd is covered by 23 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhe SunBofA Global Research
Zhe SunBofA Global Research
Yanyin ZhuChina International Capital Corporation Limited